Volume : IX, Issue : I, January - 2019

Study on median survival rate of patients treated for glioblastoma multiforme.

T Arunan, T. Suresh Babu

Abstract :

Introduction Glioblastoma multiforme is a primary ain neoplasm, consisting of a phenotypically and genotypically heterogeneous group of tumours. About ninety percent of glioblastoma cases develop de novo from normal glial cells by multistep tumorigenesis (Primary glioblastoma). The remaining10% of gliomas are cases of secondary neoplasm, developing through progression from low–grade tumours (diffuse or anaplasticastrocytomas) which takes about 4–5 years. Secondary glioma is diagnosed mostlyin persons with the mean age 39 years, grows more slowly and has a better prognosis. Management remains palliative and includes surgery, radiotherapy (RT), and chemotherapy. With optimal treatment, patients with GBs have a median survival of less than one year.About 2% of patients survive three years.Previously reported long–term survivors (LTSs) of GB may have been patients who actually harboured other low–grade gliomas .The overall prognosis for GBM has been changed little since the 1980s, despite major improvements in neuroimaging, neurosurgery, radiotherapy, and chemotherapy techniques. This study was planned and conducted to assess the median survival rate in patients with glioblastoma multiforme. Materials and methods After obtaining institutional ethical committee approval, this study was conducted on patients who underwent surgery for GBM at Institute of Neurosurgery, GGH&MMC, Chennai in the age group of less than 65 years with biopsy reported as glioblastoma multiforme in the supratentorial region. Datas regarding presenting clinical features including clinical signs and symptoms were collected.The pre operative scan& MRI findings were recorded. The surgical treatment details such as date of surgery, intra–op findings like size of the tumour, location of tumour ,type of resection performed(i.e. total, partial or biopsy) were noted.In those patients who underwent radiotherapy and chemotherapy postoperatively, the following parameters like type of radiation, its dose and completeness of cycle, complications, repeat RT if any were observed. Chemotherapy details such as drug, dosage, completeness of cycle and complications were recorded. The performance status of these patients were analysed using Karnofsky and WHO/ ECOG/ Zuod scoring system. Results– The median survival rate of GBM patients who got treated in our Institute MMC & GGH during the study period was 14 months. Age group, preop Karnofsky score, type of surgery, adjuvant RT and chemotherapy are the main factors which influence the median survival rate of GBM patients. Patients who underwent total resection and completed full dose of radiation and chemotherapy with preop Karnofsky score more than 80 had longer survival period. Glioblastoma multiforme still has a dismal prognosis and requires further research in other modalities of treatment to improve the median survival period of patients with GBM

Keywords :

Article: Download PDF   DOI : 10.36106/ijar  

Cite This Article:

STUDY ON MEDIAN SURVIVAL RATE OF PATIENTS TREATED FOR GLIOBLASTOMA MULTIFORME., T Arunan, T.Suresh Babu INDIAN JOURNAL OF APPLIED RESEARCH : Volume-9 | Issue-1 | January-2019

Number of Downloads : 183

References :